nach oben

Erschienen in:

31.08.2021 | Main topic

Patent foramen ovale—When to close and how?

verfasst von: Aurel Maloku, Ali Hamadanchi, Marcus Franz, Gudrun Dannberg, Albrecht Günther, Carsten Klingner, P. Christian Schulze, Sven Möbius-Winkler

Erschienen in: Herz | Ausgabe 5/2021

Einloggen, um Zugang zu erhalten

Abstract

Closure of a patent foramen ovale (PFO) in patients after cryptogenic/cardioembolic stroke is recommended by current guidelines for patients who are 16–60 years of age with a high-risk PFO (class of recommendation A, level of evidence I). The use of double-disk occlusion devices followed by antiplatelet therapy is recommended. The procedure of interventional PFO closure compared with other interventions in cardiology is rather easy to learn. However, it should be performed carefully to avoid postinterventional complications. The number needed to treat (NNT) to avoid one stroke in 5 years in the RESPECT trial was 42, in the CLOSE trial even lower with 20. In the REDUCE trial, the NNT was 28 at 2 years. This can be reduced by longer follow-up, e.g., at 10 years the NNT is 18. While other conditions such as migraine are currently under investigation with respect to the impact of PFO closure, sufficiently powered trials are lacking so that closure in diseases other than stroke should always be individualized.

Lee PH et al (2018) Cryptogenic stroke and high-risk patent foramen ovale: the DEFENSE-PFO trial. J Am Coll Cardiol 71(20):2335–2342PubMedCrossRef

Mas JL et al (2017) Patent foramen Ovale closure or anticoagulation vs. antiplatelets after stroke. N Engl J Med 377(11):1011–1021PubMedCrossRef

Søndergaard L et al (2017) Patent foramen ovale closure or antiplatelet therapy for cryptogenic stroke. N Engl J Med 377(11):1033–1042PubMedCrossRef

Elgendy AY et al (2020) Proposal for updated nomenclature and classification of potential causative mechanism in patent foramen ovale-associated stroke. JAMA Neurol 77(7):878–886PubMedCrossRef

Pristipino C et al (2021) European position paper on the management of patients with patent foramen ovale. Part II—Decompression sickness, migraine, arterial deoxygenation syndromes and select high-risk clinical conditions. Eur Heart J 42(16):1545–1553PubMedCrossRef

Moore KL, Persaud TVN, Torchia MG (1998) The developing human: clinically oriented embryology, 10th edn. Elsevier, Amsterdam

Naqvi N, McCarthy KP, Ho SY (2018) Anatomy of the atrial septum and interatrial communications. J Thorac Dis 10(Suppl 24):S2837–S2847PubMedPubMedCentralCrossRef

Rigatelli G, Zuin M (2016) Leonardo da Vinci and patent foramen ovale: an historical perspective. Int J Cardiol 222:826PubMedCrossRef

Hagen PT, Scholz DG, Edwards WD (1984) Incidence and size of patent foramen ovale during the first 10 decades of life: an autopsy study of 965 normal hearts. Mayo Clin Proc 59(1):17–20PubMedCrossRef

10.

Meissner I et al (1999) Prevalence of potential risk factors for stroke assessed by transesophageal echocardiography and carotid ultrasonography: the SPARC study. Mayo Clin Proc 74(9):862–869PubMedCrossRef

11.

Siu SC, Silversides CK (2010) Bicuspid aortic valve disease. J Am Coll Cardiol 55(25):2789–2800PubMedCrossRef

12.

Rodriguez CJ et al (2003) Race-ethnic differences in patent foramen ovale, atrial septal aneurysm, and right atrial anatomy among ischemic stroke patients. Stroke 34(9):2097–2102PubMedCrossRef

13.

Hara H et al (2005) Patent foramen Ovale: current pathology, pathophysiology, and clinical status. J Am Coll Cardiol 46(9):1768–1776PubMedCrossRef

14.

Steiner MM et al (1998) Patent foramen ovale size and embolic brain imaging findings among patients with ischemic stroke. Stroke 29(5):944–948PubMedCrossRef

15.

Hausmann D, Mügge A, Daniel WG (1995) Identification of patent foramen ovale permitting paradoxic embolism. J Am Coll Cardiol 26(4):1030–1038PubMedCrossRef

16.

Maffè S et al (2010) Transthoracic second harmonic two- and three-dimensional echocardiography for detection of patent foramen ovale. Eur J Echocardiogr 11(1):57–63PubMedCrossRef

17.

Naqvi TZ, Rafie R, Daneshvar S (2010) Original Investigations. Potential faces of patent foramen ovale (PFO PFO). Echocardiography 27(8):897–907PubMedCrossRef

18.

Rana BS et al (2010) Three-dimensional imaging of the atrial septum and patent foramen ovale anatomy: defining the morphological phenotypes of patent foramen ovale. Eur J Echocardiogr 11(10):19–25CrossRef

19.

Rana BS et al (2010) Echocardiographic evaluation of patent foramen ovale prior to device closure. JACC Cardiovasc Imaging 3(7):749–760PubMedCrossRef

20.

Ahmed N et al (2019) Consensus statements and recommendations from the ESO-Karolinska Stroke Update Conference, Stockholm 11–13 November 2018. Eur Stroke J 4(4):307–317PubMedPubMedCentralCrossRef

21.

Silvestry FE et al (2015) Guidelines for the echocardiographic assessment of atrial septal defect and patent foramen ovale: from the American Society of Echocardiography and Society for Cardiac Angiography and Interventions. J Am Soc Echocardiogr 28(8):910–958PubMedCrossRef

22.

23.

Di Tullio MR et al (2007) Patent foramen ovale and the risk of ischemic stroke in a multiethnic population. J Am Coll Cardiol 49(7):797–802PubMedCrossRef

24.

Sacco RL et al (2013) An updated definition of stroke for the 21st century: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 44(7):2064–2089PubMedCrossRef

25.

Caplan LR (2009) Basic pathology, anatomy, and pathopysiology of stroke. In: Caplan’s stroke: a clinical approach, 4th edn. Saunders, Philadelphia, p 22CrossRef

26.

Adams HP Jr et al (1993) Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in acute stroke treatment. Stroke 24(1):35–41PubMedCrossRef

27.

Krishnamurthi RV et al (2013) Global and regional burden of first-ever ischaemic and haemorrhagic stroke during 1990–2010: findings from the Global Burden of Disease Study 2010. Lancet Glob Health 1(5):e259–81PubMedPubMedCentralCrossRef

28.

Feigin VL et al (2014) Global and regional burden of stroke during 1990–2010: findings from the Global Burden of Disease Study 2010. Lancet 383(9913):245–254PubMedPubMedCentralCrossRef

29.

Kohler M et al (2014) Schlaganfallgeschehen in Deutschland – Zur Vergleichbarkeit von Krankenkassen‑, Register- und DRG-Daten. Fortschr Neurol Psychiatr 82(11):627–633PubMedCrossRef

30.

Nimptsch U, Mansky T (2012) Trends in acute inpatient stroke care in Germany- an observational study using administrative hospital data from 2005–2010. Dtsch Arztebl Int 109(51–52):885–892PubMedPubMedCentral

31.

Kolominsky-Rabas PL et al (2001) Epidemiology of ischemic stroke subtypes according to TOAST criteria. Stroke 32(12):2735–2740PubMedCrossRef

32.

Cohnheim J (1877) Vorlesungen uber allgemeine Pathologie – ein Handbuch fur Aerzte und Studirende, 1st edn. vol 1. Hirschwald, Berlin, p 169

33.

Lippmann H, Rafferty T (1993) Patent foramen ovale and paradoxical embolization: a historical perspective. Yale J Biol Med 66(1):11–17PubMedPubMedCentral

34.

Litten M (1880) Pathologisch-anatomisch Beobachtungen I, Ueber einen Fall von infiltriertem Leberkrebs, nebst epikritischen Bemerkungen. II. Ueber embolische Muskelveranderung und die Resorption todter Muskelfasern. Virchwos Arch 80:269–295CrossRef

35.

Saver JL (2016) Cryptogenic stroke. N Engl J Med 374(21):2065–2074PubMedCrossRef

36.

Madani H, Ransom PA (2007) Paradoxical embolus illustrating speed of action of recombinant tissue plasminogen activator in massive pulmonary embolism. Emerg Med J 24(6):441PubMedPubMedCentralCrossRef

37.

Choong CK et al (2008) Life-threatening impending paradoxical embolus caught “red-handed”: successful management by multidisciplinary team approach. J Thorac Cardiovasc Surg 136(2):527–528.e8PubMedCrossRef

38.

Carroll JD et al (2013) Closure of patent foramen ovale versus medical therapy aftercryptogenic stroke. N Engl J Med 368(12):1092–1100PubMedCrossRef

39.

Furlan AJ et al (2012) Closure or medical therapy for cryptogenic stroke with patent foramen ovale. N Engl J Med 366(11):991–999PubMedCrossRef

40.

Meier B et al (2013) Percutaneous closure of patent foramen ovale in cryptogenic embolism. N Engl J Med 368(12):1083–1091PubMedCrossRef

41.

Saver JL et al (2017) Long-term outcomes of patent foramen ovale closure or medical therapy after stroke. N Engl J Med 377(11):1022–1032PubMedCrossRef

42.

Mas J‑L et al (2017) Patent foramen ovale closure or anticoagulation vs. antiplatelets after stroke. N Engl J Med 377(11):1011–1021PubMedCrossRef

43.

Diener H‑C, Grau A, Baldus S et al (2018) Kryptogener Schlaganfall und offenes Foramen ovale, S2eLeitlinie. In: Deutsche Gesellschaft für Neurologie (Hrsg.), Leitlinien für Diagnostik und Therapie in der Neurologie. https://www.dgn.org/leitlinien. Accessed 26 May 2021

44.

Turc G et al (2018) Closure, anticoagulation, or antiplatelet therapy for cryptogenic stroke with patent foramen ovale: systematic review of randomized trials, sequential meta-analysis, and new insights from the CLOSE study. J Am Heart Assoc 7:e008356. https://doi.org/10.1161/JAHA.117.008356CrossRefPubMedPubMedCentral

45.

Darmoch F et al (2018) Transcatheter closure of patent foramen ovale versus medical therapy after cryptogenic stroke: a meta-analysis of randomized controlled trials. Cerebrovasc Dis 45(3):162–169PubMedCrossRef

46.

Abo-Salem E et al (2018) Patent foramen ovale closure versus medical therapy in cases with cryptogenic stroke, meta-analysis of randomized controlled trials. J Neurol 265(3):578–585PubMedCrossRef

47.

AWMF LL-Entwicklung: Formulierung und Graduierung von Empfehlungen. https://www.awmf.org/leitlinien/awmf-regelwerk.html (AWMF Online. Das Portal der wissenschaftlichen Medizin). Accessed 9 July 2021

48.

Lechat P et al (1988) Prevalence of patent foramen ovale in patients with stroke. N Engl J Med 318(18):1148–1152PubMedCrossRef

49.

Kent DM et al (2013) An index to identify stroke-related vs incidental patent foramen ovale in cryptogenic stroke. Neurology 81(7):619–625PubMedPubMedCentralCrossRef

50.

Wilmshurst PT et al (2000) Effect on migraine of closure of cardiac right-to-left shunts to prevent recurrence of decompression illness or stroke or for haemodynamic reasons. Lancet 356(9242):1648–1651PubMedCrossRef

51.

West BH et al (2018) Frequency of patent foramen ovale and migraine in patients with cryptogenic stroke. Stroke 49(5):1123–1128PubMedPubMedCentralCrossRef

52.

Khessali H et al (2012) The effect of patent foramen ovale closure on visual aura without headache or typical aura with migraine headache. JACC Cardiovasc Interv 5(6):682–687PubMedCrossRef

53.

Kanwar SM et al (2016) Coincidental impact of transcatheter patent foramen ovale closure on migraine with and without aura—A comprehensive meta-analysis. Clin Trials Regul Sci Cardiol 15:7–13PubMedPubMedCentralCrossRef

54.

Zhang QQ et al (2021) The efficacy of percutaneous patent foramen ovale closure on migraine: a meta-analysis of randomized controlled trials and observational studies. Biomed Res Int 2021:6643266PubMedPubMedCentral

55.

Landzberg MJ et al (1995) Orthodeoxia-platypnea due to intracardiac shunting—Relief with transcatheter double umbrella closure. Cathet Cardiovasc Diagn 36(3):247–250PubMedCrossRef

56.

Blanche C et al (2013) Platypnea-orthodeoxia syndrome in the elderly treated by percutaneous patent foramen ovale closure: a case series and literature review. Eur J Intern Med 24(8):813–817PubMedCrossRef

57.

Rimoldi SF et al (2015) Patent foramen ovale closure in obstructive sleep apnea improves blood pressure and cardiovascular function. Hypertension 66(5):1050–1057PubMedCrossRef

58.

Lock JE et al (1987) Transcatheter umbrella closure of congenital heart defects. Circulation 75(3):593–599PubMedCrossRef

59.

Krumsdorf U et al (2004) Incidence and clinical course of thrombus formation on atrial septal defect and patient foramen ovale closure devices in 1,000 consecutive patients. J Am Coll Cardiol 43(2):302–309PubMedCrossRef

60.

Han YM et al (1999) New self-expanding patent foramen ovale occlusion device. Catheter Cardiovasc Interv 47(3):370–376PubMedCrossRef

61.

Filomena D et al (2021) The evolving role of echocardiography in the assessment of patent foramen ovale in patients with left-side thromboembolism. Echocardiography 38(4):657–675PubMedCrossRef

Titel: Patent foramen ovale—When to close and how?
verfasst von: Aurel Maloku
Ali Hamadanchi
Marcus Franz
Gudrun Dannberg
Albrecht Günther
Carsten Klingner
P. Christian Schulze
Sven Möbius-Winkler
Publikationsdatum: 31.08.2021
Verlag: Springer Medizin
Erschienen in: Herz / Ausgabe 5/2021
Print ISSN: 0340-9937
Elektronische ISSN: 1615-6692
DOI: https://doi.org/10.1007/s00059-021-05061-y

Neu im Fachgebiet Kardiologie

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

17.05.2024 Plötzlicher Herztod Nachrichten

Ein signifikanter Anteil der Fälle von plötzlichem Herztod ist genetisch bedingt. Um ihre Verwandten vor diesem Schicksal zu bewahren, sollten jüngere Personen, die plötzlich unerwartet versterben, ausnahmslos einer Autopsie unterzogen werden.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

17.05.2024 Vorhofflimmern Nachrichten

Nicht nur ein vergrößerter, sondern auch ein kleiner linker Ventrikel ist bei Vorhofflimmern mit einer erhöhten Komplikationsrate assoziiert. Der Zusammenhang besteht nach Daten aus China unabhängig von anderen Risikofaktoren.

Semaglutid bei Herzinsuffizienz: Wie erklärt sich die Wirksamkeit?

17.05.2024 Herzinsuffizienz Nachrichten

Bei adipösen Patienten mit Herzinsuffizienz des HFpEF-Phänotyps ist Semaglutid von symptomatischem Nutzen. Resultiert dieser Benefit allein aus der Gewichtsreduktion oder auch aus spezifischen Effekten auf die Herzinsuffizienz-Pathogenese? Eine neue Analyse gibt Aufschluss.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2021

Pushing the limits for interventional treatment of aortic valve stenosis

Aktuelle Technologien zur interventionellen Therapie der Trikuspidalklappeninsuffizienz

Catheter-directed therapy in pulmonary embolism

Technisches Rüstzeug für chronisch verschlossene Gefäße